UPDATE : Monday, September 7, 2020
상단여백
‘Diabetes treatment Forxiga born as new heart drug in DAPA-HF study’
“The DAPA-HF trial results announced in the recent European Society of Card...
by Kim Yun-mi  |  2019-09-23 11:45
라인
Takeda Korea labor union to ask Japanese headquarters about restructuring
Takeda Pharmaceutical Korea’s trade union, in dispute with management durin...
by Kim Yun-mi  |  2019-09-19 14:11
라인
Korea unlikely to include hepatitis C test in state-backed health checkup
The government is unlikely to designate a hepatitis C antibody test as a he...
by Kim Yun-mi  |  2019-09-18 15:50
라인
Will Tagrisso study results affect use of EGFR TKIs in lung cancer?
AstraZeneca’s imminent announcement of overall survival (OS) data of Tagris...
by Kim Yun-mi  |  2019-09-18 11:36
라인
‘Lundbeck to work with parliament to prevent suicide in Korea’
Lundbeck, which sells anti-depressants Lexapro and Brintellix, dementia tre...
by Kim Yun-mi  |  2019-09-17 15:19
라인
Lenvima to get benefit as 1st-line treatment of hepatocellular carcinoma
Lenvima (ingredient: lenvatinib), a new liver cancer drug that arrived in a...
by Kim Yun-mi  |  2019-09-16 16:20
라인
FDA warns against pneumonitis with CDK 4/6 inhibitor drugs for breast cancer
The U.S. Food and Drug Administration added a warning that the entire class...
by Kim Yun-mi  |  2019-09-16 11:39
라인
AstraZeneca to challenge Roche in small-cell lung cancer treatment market
AstraZeneca’s Imfinzi (ingredient: durvalumab) has sharpened up its weapon ...
by Kim Yun-mi  |  2019-09-11 14:18
라인
PARP inhibitors to show intense rivalry at ESMO 2019
The highlight of the upcoming ESMO 2019, a cancer meeting in Europe, will b...
by Kim Yun-mi  |  2019-09-09 11:56
라인
‘No antibiotic works for patients with multidrug-resistant infections’
The number of patients with multidrug resistant bacteria such as Carbapenem...
by Kim Yun-mi  |  2019-09-06 15:11
라인
‘Government is doing best to relieve pain of atopic dermatitis patients’
The Health Insurance Review and Assessment Service (HIRA) held a closed-doo...
by Kim Yun-mi  |  2019-09-05 11:48
라인
Takeda Korea vows to release 16 new drugs by 2023
Takeda Pharmaceutical Korea on Tuesday held the first news conference after...
by Kim Yun-mi  |  2019-09-03 15:40
라인
Real-world data of Saxenda disclosed for 1st time in Asia
Korean researchers have disclosed Asia’s first real-world data of Saxenda, ...
by Kim Yun-mi  |  2019-09-02 14:39
라인
Antidiabetic Forxiga proves efficacy in heart failure
AstraZeneca said it has confirmed that its diabetes drug Forxiga (ingredien...
by Kim Yun-mi  |  2019-09-02 11:35
라인
Atopic dermatitis patients fall in despair as Dupixent may not get coverage soon
Sanofi’s new biologic agent Dupixent (ingredient: dupilumab) for severe ato...
by Kim Yun-mi  |  2019-08-30 16:26
라인
CAR-T therapy Kymriah, pie in the sky for Korean patients
Kymriah, Novartis’ new CAR-T (chimeric antigen receptor T-cell) treatment, ...
by Kim Yun-mi  |  2019-08-29 14:35
라인
‘GI Innovation will be small but strong leader of bioindustry’
“GI Innovation, armed with both basic science and development strategy, wil...
by Kim Yun-mi  |  2019-08-27 15:57
라인
‘Drug firm’s pick of doctor to attend conference overseas illegal’
Pharmaceutical companies’ support for physicians to attend academic confere...
by Kim Yun-mi  |  2019-08-22 15:45
라인
Rivalry among PARP inhibitors intense in ovarian cancer treatment
Pharmaceutical firms’ war using PARP inhibitors, a group of pharmacological...
by Kim Yun-mi  |  2019-08-19 14:00
라인
Diabetes drug Jardiance pressures heart failure treatment Entresto
Novartis’ new heart failure treatment Entresto (ingredient: sacubitril/vals...
by Kim Yun-mi  |  2019-08-09 15:44
여백
여백
여백
Back to Top